Judith Veis is a Nephrology physician affiliated with Radiance Technologies. OpenAlex indexes 37 publications with 2,860 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
110 Irving St NW
Suite 2a-38
Washington, DC 200102976
Telephone
202-877-2848Registry record last updated 8 Jul 2007.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20251 payment
- Caris MPI, Inc.Program year20251 payment
- CALLIDITAS THERAPEUTICS US INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
60.9%Calcium channel blocker11.9%Amlodipine Besylate73%Nifedipine Er27%Part D≥51 patientsLoop diuretic11.3%Furosemide88%Bumetanide12%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
12.6%SGLT2 inhibitor5.9%Jardiance51%Farxiga49%Part D<11 patientsCorticosteroid3.1%Prednisone100%Part D≥11 patients+ 3 more classes in this area
Other
8.4%Drugs for treatment of hyperkalemia and hyperphosphatemia4.5%Lokelma55%Velphoro45%Part D<11 patientsPhosphate Binder3.9%Sevelamer Carbonate75%Renvela25%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lymphoma survivors have an increased long-term risk of chronic kidney disease
Leukemia & lymphoma/Leukemia and lymphoma
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Theophilus Owan, MD
Radiance Technologies
Edward Portnay, MD
Radiance Technologies
Raghava Gollapudi, MD
Radiance Technologies
Abhilash Akinapelli, MD
Radiance Technologies
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”